Novavax Inc (NVAX) — SEC Filings
Novavax Inc (NVAX) — 50 SEC filings. Latest: 8-K (May 6, 2026). Includes 31 8-K, 6 10-Q, 4 SC 13G/A.
Overview
Novavax Inc (NVAX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 27, 2026: Novavax Inc. filed an Annual Report to Security Holders (ARS) on April 27, 2026, for the period ending December 31, 2025. The filing includes documents related to the company's operations and financial reporting. Novavax Inc. is headquartered in Gaithersburg, MD.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant filing sentiment for Novavax Inc is neutral.
Filing Type Overview
Novavax Inc (NVAX) has filed 31 8-K, 6 10-Q, 1 ARS, 3 DEFA14A, 2 DEF 14A, 1 10-K, 4 SC 13G/A, 2 SC 13D/A with the SEC between Apr 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of NVAX's 43 recent filings, 2 were flagged as high-risk, 27 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $180M |
| Net Income | -$120M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- John C. Jacobs
- Stanley C. Erck
- Dr. John C. Jacobs
- Dr. Gregory M. Glenn
- Andrew Freedman, Esq.
Industry Context
The biotechnology and pharmaceutical industry, particularly in the vaccine sector, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The post-pandemic landscape has seen a recalibration of demand for COVID-19 vaccines, impacting companies heavily reliant on these products. Competition is fierce, with established players and emerging biotechs vying for market share through innovation and strategic partnerships.
Top Tags
sec-filing (7) · financials (6) · material-agreement (5) · disclosure (5) · regulation-fd (5) · 8-K (4) · filing (4) · executive-compensation (3) · proxy-statement (3) · annual-report (2)
Executive Compensation
From the most recent DEF 14A filing (Apr 29, 2024):
- Stanley C. Erck — Member
- John C. Jacobs — Member
Key Numbers
| Metric | Value | Context |
|---|---|---|
| ARS Document Size | 17571962 | Size of the primary ARS PDF document. |
| Submission Text File Size | 24202882 | Size of the complete submission text file. |
| Q2 2025 Product Revenue | $150M | 92.8% decrease from Q2 2024 |
| Q2 2024 Product Revenue | $2.1B | Baseline for comparison |
| Q2 2025 Total Revenue | $180M | Significant decline from prior year |
| Q2 2024 Total Revenue | $2.3B | Baseline for comparison |
| Q2 2025 Net Income (Loss) | -$120M | Shift from profit to loss |
| Q2 2024 Net Income | $1.5B | Baseline for comparison |
| H1 2025 Net Income (Loss) | -$250M | Year-to-date loss |
| H1 2024 Net Income | $3.2B | Year-to-date profit in prior year |
| Product Revenue Decrease | 92.8% | Percentage drop Q2 2024 to Q2 2025 |
| End of Quarter | 2025-03-31 | Reporting period for the 10-Q |
| Beginning of Quarter | 2025-01-01 | Reporting period for the 10-Q |
| Fiscal Year End | 2024 | Reporting period for executive compensation |
| Conformed Period of Report | 20250620 | Date as of which the report is considered |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Novavax Inc (NVAX)?
Novavax Inc has 50 recent SEC filings from Apr 2024 to May 2026, including 31 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NVAX filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Novavax Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Novavax Inc (NVAX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Novavax Inc?
Key financial highlights from Novavax Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NVAX?
The investment thesis for NVAX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Novavax Inc?
Key executives identified across Novavax Inc's filings include John C. Jacobs, Stanley C. Erck, Dr. John C. Jacobs, Dr. Gregory M. Glenn, Andrew Freedman, Esq..
What are the main risk factors for Novavax Inc stock?
Of NVAX's 43 assessed filings, 2 were flagged high-risk, 27 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Novavax Inc?
Forward guidance and predictions for Novavax Inc are extracted from SEC filings as they are enriched.